Patents by Inventor Rajesh Jain

Rajesh Jain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180289793
    Abstract: The present invention relates to field of live attenuated recombinant tetravalent dengue vaccines and methods of producing stable compositions. Present invention specifically relates to a stable composition and methods of using such a stable composition comprising live attenuated recombinant dengue virus, stabilizer, bulking agent and optionally buffering agents, wherein the live attenuated dengue virus is generated from ? 30 and or ? 31 deleted or mutated dengue strains. More specifically, the present invention relates to stabilizers for freeze-dried live attenuated immunogenic and/or vaccine compositions that may comprise, inter alia, dengue virus(es). The invention further relates to stabilized, freeze-dried live attenuated immunogenic and/or vaccine compositions of, dengue virus(es), which may contain these stabilizers. Other aspects of the invention are described in or are evident from the following disclosure, and are within the ambit of the invention.
    Type: Application
    Filed: September 29, 2016
    Publication date: October 11, 2018
    Inventors: Rajesh JAIN, Sukhjeet SINGH, Lavit JAMBU
  • Patent number: 9974489
    Abstract: Described is an infant monitoring and alerting system capable of determining an absence of movement by an infant. When an absence of movement is detected the monitor attempts to stimulate movement using stimuli that may include a vibration, an audible alert, or a visual alert. If no movement is detected in response to the stimuli, the monitor may provide another instance of stimuli which may include stimuli at an elevated intensity or additional and/or different stimuli. The additional instance of stimuli may further attempt to stimulate movement by the infant and may also function as an alert to the caregiver that their attention may be required.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: May 22, 2018
    Assignee: CIRCUS WORLD DISPLAYS LTD.
    Inventor: Rajesh Jain
  • Patent number: 9907514
    Abstract: Described is an infant monitoring and alerting system capable of determining an absence of movement by an infant. When an absence of movement is detected the monitor attempts to stimulate movement using stimuli that may include a vibration, an audible alert, or a visual alert. If no movement is detected in response to the stimuli, the monitor may provide another instance of stimuli which may include stimuli at an elevated intensity or additional and/or different stimuli. The additional instance of stimuli may further attempt to stimulate movement by the infant and may also function as an alert to the caregiver that their attention may be required.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: March 6, 2018
    Assignee: CIRUS WORLD DISPLAYS LTD.
    Inventor: Rajesh Jain
  • Publication number: 20180014221
    Abstract: User equipments (UEs) may be scheduled by determining relative priorities of data radio bearers (DRBs), each DRB associated with a respective UE. A limit is established dividing radio resources available for allocation in the cell during a scheduling period into at least a first limited portion and a second remaining portion. According to the determined relative priorities: a) up to the first limited portion of the radio resources are allocated to only the DRBs that have a guaranteed bit rate (GBR), and thereafter b) the second remaining portion of the radio resources are allocated to only the DRBs which have not been fully allocated from the first limited portion. Schedules indicating this allocation are transmitted to the respective UEs. In carrier aggregation where each carrier aggregated cells has a respective plurality of DRBs, relative priorities for each respective plurality of DRBs are determined for each carrier aggregated cell.
    Type: Application
    Filed: September 8, 2017
    Publication date: January 11, 2018
    Inventors: Mayank Kumar Rastogi, Rajiv Gupta, Rajesh Jain, Tauheed Ahmed
  • Patent number: 9788233
    Abstract: User equipments (UEs) may be scheduled by, in a cell, determining relative priorities of data radio bearers (DRBs), each DRB associated with an active UE. A limit is established dividing radio resources available for allocation in the cell during a scheduling period into at least a first limited portion and a second remaining portion. According to the determined relative priorities: a) up to the first limited portion of the radio resources are allocated to only the DRBs that have a guaranteed bit rate (GBR), and thereafter b) the second remaining portion of the radio resources are allocated to only the DRBs which have not been fully allocated from the first limited portion. In carrier aggregation the radio resources are allocated in turn in each different cell per step a) and thereafter in turn in each different cell per step b).
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: October 10, 2017
    Assignee: Aricent Holdings Luxembourg S.A.R.L.
    Inventors: Mayank Kumar Rastogi, Rajiv Gupta, Rajesh Jain, Tauheed Ahmed
  • Patent number: 9668171
    Abstract: To schedule user equipments (UEs) in a scheduling period, for each of X cells in a carrier aggregation (CA) system relative priorities of data bearers are determined. Each data bearer is associated with a respective UE having buffered data and at least one of the UEs is a CA-UE that is allowed radio resource allocation to its associated data bearers in at least two of the cells. For each CA-UE, the buffered data of the CA-UE is distributed across those cells in which the CA-UE and its associated bearers are allowed resource allocation using a measure of total data throughput for each of those cells. For each of the X cells resources are allocated to the data bearers according to the relative priorities such that for each CA-UE the resources allocated to its associated data bearers across those cells are sufficient to carry the buffered data as distributed.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: May 30, 2017
    Assignee: Aricent Holdings Luxembourg S.A.R.L.
    Inventors: Rajiv Gupta, Mayank Kumar Rastogi, Rajesh Jain, Gaurav Goel, Tauheed Ahmed
  • Patent number: 9642808
    Abstract: Extended release pharmaceutical compositions comprising mycophenolate sodium as the active agent, wherein the said composition exhibits a characteristic release profile when subjected to in-vitro dissolution study, and wherein said mycophenolate sodium is released in a sustained manner in-vivo for a prolonged duration in such quantities that substantially alleviates or at least reduces the chances of causing any associated gastrointestinal side effect(s) without compromising the bioavailability of the said active agent are provided. The present invention also provides process of preparing dosage form compositions and prophylactic and/or therapeutic methods of using such dosage form. The compositions of the present invention are useful for the management such as prophylaxis, amelioration and/or treatment of immunosuppressant indicated disease(s)/disorder(s) especially for the treatment or prevention of organ, tissue or cellular allograft or xenograft rejection, e.g.
    Type: Grant
    Filed: August 11, 2008
    Date of Patent: May 9, 2017
    Assignee: PANACEA BIOTECH LIMITED
    Inventors: Rajesh Jain, Sukhjeet Singh, Sampath Kumar Devarajan
  • Publication number: 20160345915
    Abstract: Described is an infant monitoring and alerting system capable of determining an absence of movement by an infant. When an absence of movement is detected the monitor attempts to stimulate movement using stimuli that may include a vibration, an audible alert, or a visual alert. If no movement is detected in response to the stimuli, the monitor may provide another instance of stimuli which may include stimuli at an elevated intensity or additional and/or different stimuli. The additional instance of stimuli may further attempt to stimulate movement by the infant and may also function as an alert to the caregiver that their attention may be required.
    Type: Application
    Filed: October 1, 2015
    Publication date: December 1, 2016
    Inventor: Rajesh Jain
  • Publication number: 20160345914
    Abstract: Described is an infant monitoring and alerting system capable of determining an absence of movement by an infant. When an absence of movement is detected the monitor attempts to stimulate movement using stimuli that may include a vibration, an audible alert, or a visual alert. If no movement is detected in response to the stimuli, the monitor may provide another instance of stimuli which may include stimuli at an elevated intensity or additional and/or different stimuli. The additional instance of stimuli may further attempt to stimulate movement by the infant and may also function as an alert to the caregiver that their attention may be required.
    Type: Application
    Filed: June 1, 2015
    Publication date: December 1, 2016
    Inventor: Rajesh Jain
  • Patent number: 9402808
    Abstract: The present invention relates to liquid oral pharmaceutical compositions of lanthanum and its pharmaceutically acceptable salts thereof. The present invention further relates to preparation of liquid oral pharmaceutical compositions of lanthanum and its salts and also provides use of such compositions in treating hyperphosphatemia in patients.
    Type: Grant
    Filed: January 17, 2012
    Date of Patent: August 2, 2016
    Assignee: PANACEA BIOTEC LIMITED
    Inventors: Rajesh Jain, Sarabjit Singh, Paramjit Singh, Pirthi Pal Singh
  • Publication number: 20160143046
    Abstract: To schedule user equipments (UEs) in a scheduling period, for each of X cells in a carrier aggregation (CA) system relative priorities of data bearers are determined. Each data bearer is associated with a respective UE having buffered data and at least one of the UEs is a CA-UE that is allowed radio resource allocation to its associated data bearers in at least two of the cells. For each CA-UE, the buffered data of the CA-UE is distributed across those cells in which the CA-UE and its associated bearers are allowed resource allocation using a measure of total data throughput for each of those cells. For each of the X cells resources are allocated to the data bearers according to the relative priorities such that for each CA-UE the resources allocated to its associated data bearers across those cells are sufficient to carry the buffered data as distributed.
    Type: Application
    Filed: November 18, 2014
    Publication date: May 19, 2016
    Inventors: Rajiv GUPTA, Mayank Kumar RASTOGI, Rajesh JAIN, Gaurav GOEL, Tauheed AHMED
  • Publication number: 20160142933
    Abstract: User equipments (UEs) may be scheduled by, in a cell, determining relative priorities of data radio bearers (DRBs), each DRB associated with an active UE. A limit is established dividing radio resources available for allocation in the cell during a scheduling period into at least a first limited portion and a second remaining portion. According to the determined relative priorities: a) up to the first limited portion of the radio resources are allocated to only the DRBs that have a guaranteed bit rate (GBR), and thereafter b) the second remaining portion of the radio resources are allocated to only the DRBs which have not been fully allocated from the first limited portion. In carrier aggregation the radio resources are allocated in turn in each different cell per step a) and thereafter in turn in each different cell per step b).
    Type: Application
    Filed: November 14, 2014
    Publication date: May 19, 2016
    Inventors: Mayank Kumar RASTOGI, Rajiv GUPTA, Rajesh JAIN, Tauheed AHMED
  • Patent number: 9292423
    Abstract: A compatibility service monitors programs to detect compatibility issues. The compatibility service provides users, such as developers, with notifications of compatibility issues a program may experience when the program executes on a particular device and/or uses a particular operating system. In some configurations, the compatibility service detects compatibility issues by performing tests on programs using a testing service. The compatibility service may also receive notifications of incompatibilities from different sources. For example, the compatibility service may receive notifications of incompatibilities from other users (e.g., developers), web sites, and the like. The compatibility service may proactively notify developers of compatibility issues for their programs. For example, one developer may request to be notified of all detected compatibility issues, whereas another developer might request to be notified of compatibility issues that are above some specified severity level of incompatibility.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: March 22, 2016
    Assignee: Amazon Technologies, Inc.
    Inventors: Japan Shailesh Doshi, Rajesh Jain, Sanyu Kiruluta
  • Patent number: 9133116
    Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention further provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more disorders of the central and/or peripheral nervous system, preferably by modulating neurological and/or psychiatric targets (GPCR and/or non-GPCR).
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: September 15, 2015
    Assignee: PANACEA BIOTEC LTD.
    Inventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Nishan Singh, Sudhir Kumar Sharma
  • Patent number: 9018249
    Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: April 28, 2015
    Assignee: Panacea Biotec Limited
    Inventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Gurmeet Kaur Nanda, Sastry V. R. S. Thungathurthi, Nishan Singh, Sudhir Kumar Sharma
  • Publication number: 20140378540
    Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).
    Type: Application
    Filed: September 12, 2012
    Publication date: December 25, 2014
    Inventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Gurmeet Kaur Nanda, Sastry V. R. S Thungathurthi, Nishan Singh, Sudhir Kumar Sharma
  • Patent number: 8906913
    Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.
    Type: Grant
    Filed: June 22, 2010
    Date of Patent: December 9, 2014
    Assignee: Panacea Biotec Limited
    Inventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Gurmeet Kaur, Sandeep Kanwar, Nishan Singh, Gurmeet Kaur Nanda, Sitaram Kumar Magadi, Sudhir Kumar Sharma
  • Patent number: 8841306
    Abstract: The present invention relates to novel phenyl oxazolidinone compounds of formula I, their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of formula I or their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of formula I and methods of using them. The compounds of the present invention are useful as antimicrobial agents, effective against a number of aerobic and/or anaerobic Gram positive and/or Gram negative pathogens such as multi drug resistant species of Staphylococcus, Streptococcus, Enterococcus, Bacterioides, Clostridia, H.
    Type: Grant
    Filed: November 18, 2009
    Date of Patent: September 23, 2014
    Assignee: Panacea Biotec Ltd.
    Inventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Sandeep Kanwar, Sitaram Kumar Magadi, Sudhir Kumar Sharma
  • Publication number: 20140228303
    Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).
    Type: Application
    Filed: June 13, 2012
    Publication date: August 14, 2014
    Applicant: Panacea Biotec Ltd
    Inventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Gurmeet Kaur Nanda, Sastry V. R. S Thungathurthi, Nishan Singh, Sudhir Kumar Sharma
  • Publication number: 20130302383
    Abstract: The present invention relates to liquid oral pharmaceutical compositions of lanthanum and its pharmaceutically acceptable salts thereof. The present invention further relates to preparation of liquid oral pharmaceutical compositions of lanthanum and its salts and also provides use of such compositions in treating hyperphosphatemia in patients.
    Type: Application
    Filed: January 17, 2012
    Publication date: November 14, 2013
    Inventors: Rajesh Jain, Sarabjit Singh, Paramjit Singh, Pirthi Pal Singh